Coping with Job Lock

 

When you're unable to take a new job because your new employer's insurer refuses to cover certain preexisting conditions, including cancer, that's called "job lock." It reduces your job mobility and may limit your income potential.

Many people once found themselves in that predicament if they, or someone in their family, was in cancer treatment. One study of Indiana workers who had health insurance through their employers found that chronic illness reduced their job mobility by about 40 percent.

Yet you may be more fearful about job lock than is warranted. In 1997, the federal Health Insurance Portability and Accountability Act (HIPAA) was passed. It limits the exclusions for preexisting conditions. As a result, if you are in a group health plan now and are moving to a job that has coverage with another group health plan, the new insurer cannot refuse you coverage because of cancer or other preexisting conditions. This often requires that you have little or no gap in coverage, such as being uninsured for 63 days or more.

Job lock protection under HIPAA covers group health plans in every U.S. state, but each state interprets the law differently. Some will allow a "group of one" category.

Plan carefully before switching jobs:

  • Contact your state's health insurance assistance program to make sure that you won't be left uncovered.
  • Ask your current employer for a "certificate of creditable coverage" to verify that the group plan is covered under HIPAA.
  • If you're leaving to become self-employed, you may have to meet special criteria to retain coverage.
  • Haven't decided what you want to do? Make sure you have COBRA, or some sort of continuation coverage, to keep your HIPAA protection against preexisting condition clauses.
Latest Cancer News
ACS Guidelines for Breast Screening with MRI May Be Excluding Some High-risk Women

January 6, 2009 — The American Cancer Society (ACS) has developed a set of guidelines to recommend which high-risk women need to undergo screening with breast magnetic resonance imaging (MRI); however, these guidelines may unwittingly exclude some women who are at a high risk of carrying the BRCA mutation yet still don’t meet the limitations set by the ACS. The results of this study were published in the journal Cancer.

Colonoscopy Fails to Identify Many Colorectal Cancers

January 6, 2009 — Colonoscopy, a standard screening method for colorectal cancer, misses the majority of cancers on the right side of the colon and about one-third of cancers on the left side of the colon, according to the results of a study published in the Annals of Internal Medicine. The researchers estimated that the screening method may reduce colorectal cancer mortality by 60-70%, rather than 90% as previously estimated.

High-dose Faslodex® Improves Time to Progression Compared with Arimidex® as Initial Therapy in Advanced Breast Cancer

January 6, 2009 — Researchers affiliated with an international trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with Arimidex® (anastrozole) as initial therapy for hormone-positive, advanced breast cancer. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium December 10-14, 2008.

Select news items provided by Reuters Health